 |
 |
 |
 |
          |
 NVENTA HIRES VICE PRESIDENT OF CORPORATE DEVELOPMENT FOR IMMEDIATE RELEASE - June 5, 2007 San Diego, California USA - Nventa Biopharmaceuticals Corporation (TSX:NVN) announced today that Richard B. Lai Fatt, Ph.D., has joined the Company as its Vice President of Corporate Development. “Richard is a results-oriented Business/Corporate Development professional with substantial experience partnering novel drugs and drug discovery programs,” commented Gregory M. McKee, President and Chief Executive Officer at Nventa. “His experience in all facets of Corporate and Business Development, as well as hands-on expertise in strategic marketing and planning, financial modeling, portfolio management and product commercialization, will be invaluable as we advance our lead program, HspE7, and identify synergistic opportunities to collaborate with other biotechnology and pharmaceutical companies.” Prior to joining Nventa, Dr. Lai Fatt was the Vice President of Corporate Development at Kalypsys, Inc. Before Kalypsys, Dr. Lai Fatt served as Vice President, Business Development and Strategic Marketing at Isis Pharmaceuticals, where he secured several licensing and collaboration deals, including partnerships with Merck and Amgen. Earlier in his career, Dr. Lai Fatt held various positions at DuPont Merck Pharmaceuticals, Schering-Plough International, Schering Canada and Lederle Pharmaceuticals. Dr. Lai Fatt received his B.Sc. at the University of Miami, Florida, and his Ph.D. in biology at McMaster University in Hamilton, Ontario, Canada. About Nventa Biopharmaceuticals Corporation: Nventa is developing innovative therapeutics for the treatment of viral infections and cancer, with a focus on diseases caused by the human papillomavirus (HPV). The corporation is publicly traded on the Toronto Stock Exchange under the symbol NVN. For more information about Nventa Biopharmaceuticals Corporation, please visit the Company’s website located at www.nventacorp.com. Contact:
|
|||||||
 |
|
|
|
|
||||
|
||||||||